Rheumatoid arthritis

Aqtual to Present Data on Innovative Approach to Rheumatoid Arthritis Therapy Selection at CCR East 2024

Retrieved on: 
Donnerstag, Mai 9, 2024
Conditional sentence, Congress, Rheumatology, University, Birmingham School of Law, JAK, DNA, Patient, Rheumatoid arthritis, CCR, Trial of the century, Division, Pharmaceutical industry

The first poster demonstrates proof-of-concept data for a novel blood-based therapy selection test the company is developing to predict treatment response in patients with rheumatoid arthritis (RA).

Key Points: 
  • The first poster demonstrates proof-of-concept data for a novel blood-based therapy selection test the company is developing to predict treatment response in patients with rheumatoid arthritis (RA).
  • The second poster highlights their PRIMA-102 study, Aqtual's prospective observational clinical trial, which is actively enrolling and was recently expanded to include more than 800 patients.
  • The proof-of-concept data underscores the potential of Aqtual's blood-based therapy selection test to accurately measure patient responses to specific treatments.
  • "The data we are presenting at CCR East 2024 is an important step in the development of Aqtual's first therapy selection test, which will give rheumatologists a powerful tool for selecting therapy and helping their patients with RA achieve low disease activity," said Diana Abdueva, Ph.D., co-founder and CEO of Aqtual.

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Donnerstag, Mai 9, 2024
American Academy, Ulcerative colitis, BDCA2, American Association of Immunologists, CDAI, American Academy of Dermatology, PD-1, IND, Week, AAI, Therapy, Patient, Graft-versus-host disease, Rheumatoid arthritis, AAD, Atopic dermatitis, BTLA, SAN, UC, Pharmaceutical industry

“This quarter, we continued to enroll patients globally across three Phase 2 trials for our two best-in-class checkpoint agonists: ANB032, our BTLA agonist, and rosnilimab, our PD-1 agonist.

Key Points: 
  • “This quarter, we continued to enroll patients globally across three Phase 2 trials for our two best-in-class checkpoint agonists: ANB032, our BTLA agonist, and rosnilimab, our PD-1 agonist.
  • Collaboration revenue was $7.2 million for the three months ended March 31, 2024, compared to $1.4 million for the three months ended March 31, 2023.
  • Research and development expenses were $37.0 million for the three months ended March 31, 2024, compared to $35.0 million for the three months ended March 31, 2023.
  • General and administrative expenses were $12.3 million for the three months ended March 31, 2024, compared to $10.8 million for the three months ended March 31, 2023.

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Donnerstag, Mai 9, 2024
Transfer, FDA, Research, Inflammation, Cell cycle, IND, CNS, Prostate cancer, AACR, Cancer, Autoimmunity, Lung cancer, Traffic barrier, MGD, Food, European Alliance, Conference, Roche, DDW, Pericarditis, Therapy, NSCLC, Rat, Ulcerative colitis, Poster, NLRP3, CCNE1, SCLC, Finance, Triple-negative breast cancer, Consultant, Public expenditure, Obesity, Gout, GLP, DSM-IV codes, Clinical trial, Toxicology, CDK2, G&A, Investigational New Drug, MYC, Research and development, EULAR, Carcinoma, Administration, Rheumatoid arthritis, Neoplasm, POC, Dermatology, Growth, Pharmaceutical industry

“We’re excited by the significant advances made across our entire portfolio, including both our oncology and immunology/inflammation programs,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics.

Key Points: 
  • “We’re excited by the significant advances made across our entire portfolio, including both our oncology and immunology/inflammation programs,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics.
  • The Company is on track to determine the recommended Phase 2 dose (RP2D) in Q2 2024 and report Phase 1 study results in H2 2024.
  • Announce the recommended Phase 2 dose for the MRT-2359 Phase 1/2 study in Q2 2024 and report Phase 1 clinical results in H2 2024.
  • Net Loss: Net loss for the first quarter of 2024 was $32.0 million, compared to $33.3 million for the fourth quarter of 2023.

IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Mittwoch, Mai 8, 2024
PFS, Myopathy, Patient, Research and development, Investment, Colorectal cancer, Progression-free survival, Research, Immunoglobulin M, CD38, Bevacizumab, Trial of the century, Lupus, Administration, Rheumatoid arthritis, IGM, Myositis, SLE, Clinical trial, FOLFIRI, Rheumatism, GAAP, G&A

MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended March 31, 2024 and provided an update on recent developments.

Key Points: 
  • MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended March 31, 2024 and provided an update on recent developments.
  • Collaboration Revenue: For the first quarter of 2024 and 2023, collaboration revenues were $0.5 million in each quarter.
  • Research and Development (R&D) Expenses: For the first quarter of 2024, R&D expenses were $43.8 million, compared to $50.9 million for the first quarter of 2023.
  • General and Administrative (G&A) Expenses: For the first quarter of 2024, G&A expenses were $10.5 million, compared to $13.0 million for the first quarter of 2023.

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Retrieved on: 
Dienstag, Mai 7, 2024
Pancreatic cancer, ITK, Hidradenitis suppurativa, Research, ACRS, Webcast, Patient, Rheumatoid arthritis, Lilly, Interim, Atopic dermatitis, Therapy, G&A, Pharmaceutical industry

WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2024 and provided a corporate update.

Key Points: 
  • WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2024 and provided a corporate update.
  • In September 2023, Aclaris reported positive results from its Phase 1 multiple ascending dose (MAD) trial of ATI-2138.
  • Net loss was $16.9 million for the first quarter of 2024 compared to $28.2 million for the first quarter of 2023.
  • Total revenue was $2.4 million for the first quarter of 2024 compared to $2.5 million for the first quarter of 2023.

Dr. Reginald Seeto Appointed as CEO and President, to Lead Scipher Medicine's Next Phase of Growth

Retrieved on: 
Donnerstag, Mai 9, 2024
Research, General Health, Networks, Pharmaceutical, Data Management, Technology, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Other Technology, Health, Other Science, CFO, Jonathan Rothberg, McKinsey & Company, Boehringer Ingelheim, MBBS, EVP, Khosla Ventures, Growth, Medicine, Corporate development, MedImmune, Autoimmune disease, Audit committee, Patient, Rheumatoid arthritis, Reg, Independent, AstraZeneca, Management

Scipher Medicine, an AI-enabled precision immunology company, today announced the appointment of Reginald Seeto, MBBS*, as Chief Executive Officer and President.

Key Points: 
  • Scipher Medicine, an AI-enabled precision immunology company, today announced the appointment of Reginald Seeto, MBBS*, as Chief Executive Officer and President.
  • Dr. Seeto is a seasoned CEO and Board Member who brings more than two decades of leadership experience across both diagnostic and therapeutic companies.
  • Dr. Seeto was most recently the CEO and President of CareDx ("CDNA"), a company focused on the transplant patient.
  • Seeto and Muir’s appointment mark a significant step forward for Scipher as the company positions itself for continued growth within the field of precision immunology.

Autoimmune Disease Diagnostics Market Research, Size, Global Forecasts 2024-2030: Robotics and AI, Autoantibody Assays and Genetic Testing, & Innovative Biomarkers Drive Expansion - ResearchAndMarkets.com

Retrieved on: 
Donnerstag, Mai 9, 2024
Robotics, Medical Devices, Health, Technology, Health Technology, Artificial Intelligence, Mortality, Diagnosis, AI, Prognosis, Research, Heart, Diabetes, Insurance, SADS, Genetic testing, Point-of-care testing, Automation, Autoimmune disease, Arthritis, Patient, Inflammatory bowel disease, Rheumatoid arthritis, Physician, Consciousness, Arthritis Foundation, Lupus, Biomarker, Wipro, Multiple sclerosis, Disease, Vaccine

The growing old global population, specifically susceptible to autoimmune illnesses, fuels a growing diagnostics market.

Key Points: 
  • The growing old global population, specifically susceptible to autoimmune illnesses, fuels a growing diagnostics market.
  • By product, the global autoimmune diseases diagnostics market is fragmented into Therapeutic & Monitoring Equipment, Diagnostics Equipment, and Drugs.
  • The global autoimmune diseases diagnostics market is segmented into Systemic Autoimmune Disease Diagnostics and Localized Autoimmune Disease Diagnostics.
  • By indication, the global autoimmune diseases diagnostics market is categorized into Rheumatic Disease, Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, and Others.

PLK Targeted Therapies Market & Clinical Trials 2024: Onvansertib Leading the Way in PLK1 Inhibition, Pioneering Breakthroughs in Small Cell Lung Cancer and Chronic Myelomonocytic Leukemia Treatment - ResearchAndMarkets.com

Retrieved on: 
Dienstag, Mai 7, 2024
Health, Clinical Trials, Cytokinesis, Immunotherapy, Cancer, Chronic myelomonocytic leukemia, Inflammation, Disorder, Safety, Breast cancer, Viral, Apoptosis, SCLC, Cell proliferation, Research, Cell cycle, Carcinoma, DNA, Mitosis, Indication, Patient, Rheumatoid arthritis, Hepatitis B virus, Virus, Proteolysis targeting chimera, Multiple sclerosis, HIV, Messenger, PLK, Lupus, Genome, Biomarker, Medicine, PLK1, DA, HBV, Pharmaceutical industry

The "Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.
  • Onvansertib, a PLK1 inhibitor developed by Cardiff Oncology, is currently the most advanced candidate in clinical trials.
  • The progression of these candidates through the pipeline reflects the growing interest and confidence in PLK targeted therapies.
  • In conclusion, PLK targeted therapies are a rapidly developing field with revolutionary promise across a wide range of disease areas.

Hawaii Specialty Pharmacy Announces New Ambulatory Infusion Centers to Serve Maui Community, Invites Local Media and Community Members to Opening Reception

Retrieved on: 
Mittwoch, Mai 8, 2024
Physician, Ulcerative colitis, Makawao, Hawaii, Patient, Cancer, Pharmacy, Hospital, Health, Heart, Chronic inflammatory demyelinating polyneuropathy, Nursing, Doctor of Pharmacy, Rheumatoid arthritis, HSP, Multiple sclerosis, CIDP

MAKAWAO, Hawaii, May 8, 2024 /PRNewswire/ -- Hawaii Specialty Pharmacy (HSP), a leading provider of specialty infusion pharmacy services with a focus on high-touch patient care and a mission to optimize patient health, today announced the opening of two new ambulatory infusion centers in Maui, Hawaii.

Key Points: 
  • MAKAWAO, Hawaii, May 8, 2024 /PRNewswire/ -- Hawaii Specialty Pharmacy (HSP), a leading provider of specialty infusion pharmacy services with a focus on high-touch patient care and a mission to optimize patient health, today announced the opening of two new ambulatory infusion centers in Maui, Hawaii.
  • "Empowering our community with comprehensive healthcare solutions has always been at the heart of Hawaii Specialty Pharmacy's mission," says George Kridner, PharmD, CEO of Hawaii Specialty Pharmacy.
  • Since its inception in 2018, Hawaii Specialty Pharmacy has distinguished itself by offering a local and personalized approach to patients managing complex and rare conditions.
  • Maui is excited to welcome these new infusion centers and their staff into the heart of our community."

FDA Roundup: April 26, 2024

Retrieved on: 
Freitag, April 26, 2024
FDA, Lutetium (177Lu) oxodotreotide, Sale, Answer, Public, Report, Cosmetics, Syringe, Dietary supplement, News, Safety, DCM, Food, Research, Human services, GFI, Animal, Dilated cardiomyopathy, Cardinal Health, Commitment, Diabetes, Furosemide, Glomus tumor, Vaccine, Development, VFD, Osteoporosis, Novartis, BRAF, Inflammatory bowel disease, Tablet, Patient, Rheumatoid arthritis, Psoriasis, Heated tobacco product, Macular degeneration, Multimedia, Dog, Cancer, LGG, Food and Drug Administration, BRAF V600, Heart, Pharmaceutical industry

On Thursday, the FDA announced it has approved the first generic pimobendan for the management of congestive heart failure in dogs.

Key Points: 
  • On Thursday, the FDA announced it has approved the first generic pimobendan for the management of congestive heart failure in dogs.
  • The FDA expects this firm to fully address the violations described in the warning letter.
  • This represents the first FDA approval of a radioactive drug, or radiopharmaceutical, for pediatric patients 12 years of age and older with SSTR-positive GEP-NETs.
  • This represents the first FDA approval of a systemic therapy for the treatment of patients with pediatric LGG with BRAF rearrangements, including fusions.